Skip to main content
ResMed Inc.
Healthcare · Medical Instruments & Supplies
Made on Aug 4, 2026
Price at call $215.19
6-month call Neutral +2.7%
Target by Feb 2027 $221.00
Great value below $180.00
Model v0.6.0

Projection vs Actual (6M history + forecast)

The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change +2.7% to $221.00
Predicted High $221.00 at 6 months
Predicted Low $213.00 at 1 month
Max Drawdown (predicted) -1.0%

Forecast

The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded. Predicted Aug 4, 2026 2:49 am
Neutral RMD trends range-bound to $221.00 (+2.7% from $215.19) by Feb 2027. dip-then-recover
ThesisRMD trades near composite fair value with weak 6-month momentum but strong quality and a constructive tape; expect a slow grind toward the signal-adjusted anchor near $218-220 with modest early drift and mild appreciation as the durable compounder narrative reasserts itself absent an earnings catalyst.
Invalidated ifA break below $200 on volume or a negative pre-announcement would falsify the mild-recovery path; a sustained move above $230 would mean the thesis is too conservative.
Checkpointtime after the call Datewhen it gets graded Predictedthe claim: closing price Current priceactual close — fills in over time Predicted returnpredicted vs $215.19 at call Conv.brain's confidence, 1–10 Driverwhy the brain put the point here
Prediction made Aug 4, 2026 $215.19 at call The anchor — every point below is measured from this price and date.
2 weeks Aug 18, 2026 $199.63–$230.75 typical range · internal point $214.50 ±7.2% 6/10 Low-beta drift near current with weak momentum tail
What actually happened: closed $220.37 on Aug 17, 2026 = +2.4% vs the call (predicted -0.3%)  ·  direction HIT (called flat, was flat)  ·  off by 2.7 pp  ·  accuracy 9/10  ·  typical range ±7.2%: inside the band  ·  S&P +0.6% over the same window — lagged it
1 month Sep 4, 2026 $192.64–$237.74 typical range · internal point $213.00 ±10.5% 5/10 Slight sag as recent 6mo weakness lingers
2 months Oct 4, 2026 $215.50 +0.1% 5/10 Stabilization as tape stays risk-on, no catalyst
3 months Nov 4, 2026 $218.00 +1.3% 5/10 Q4 print risk resolves; quality bid returns
4 months Dec 4, 2026 $219.50 +2.0% 4/10 Value gravity pulls toward signal-adjusted anchor
5 months Jan 4, 2027 $220.00 +2.2% 4/10 Year-turn positioning favors durable compounders
6 months Feb 4, 2027 $221.00 +2.7% 3/10 Mild appreciation toward composite fair value zone

Why ranges on the short rungs? A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here — three prompt formulations all lost to simply predicting zero — while the stock's own volatility scale (σ×√t) described those windows well. So the short rungs claim what's actually knowable: the typical travel, with earnings timing flagged where the variance will come from. The internal point calls keep being generated and graded to map where real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.

Deterministic control (v0.3 value line) targets $215.78 (+0.3%) — both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it. Brain: claude-opus-4-7.

Weaknesses

0 blocking · 1 degraded · 0 notes — follow the chain top-down (cause → effect).
  • Degraded
    [caution] Sector in contraction — demand weakening across the industry
    upstream:valuation-synthesis

Equation Inputs

Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.

Value anchors (from deep analysis)

Price at call$215.19
Composite fair value$208.84
Signal-adjusted fair value$218.66
DCF fair value$167.69
Anchored-PE fair value$403.95
Buy-below (value lens)$180.00
Value net score-44
Value confidence7 / 10
Quality net score+80
Memo confidence7 / 10
Deserved value (base)
Quality tilt
Deserved value (used)
Coherence (value × quality)

Price behaviour (trailing — shapes the realism line)

Realized volatility (annualized) 1m 41.8%  3m 36.3%  6m 32.8%  
Daily σ (realism noise)2.3%
Beta vs S&P 500 1m 0.04  3m -0.16  5m 0.32  
Trailing 6-month return-17.1%

Knobs (equation params)

ladderArray
llm_modelclaude-opus-4-7
max_tokens3000
control_knobsArray
Neutral band (%)5
earnings_briefv1
prompt_versionp1
control_versionv0.3.0

Version & Tech Chain

What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model v0.6.0 #271041f8fcd5

Tech composition (what this version is built from)

#ProcessKindGroup
1 Synthesis valuation-synthesis deterministic final
2 Scenario Analysis scenario-valuation deterministic valuation
3 Valuation / Mispricing ext-lens-value llm extended
4 Company Quality ext-lens-quality llm extended
5 Forensic Memo (combiner) ext-forensic-memo llm extended
6 Classification company-classification llm foundation
7 Live Quote fmp-quote data market-data

Inputs used (the runs that fed this prediction)

Upstream processRanLagRun id
company-classification Aug 3, 2026 freshest RMD-20260803-124727-a9dc
ext-forensic-memo Aug 3, 2026 freshest ext-RMD-20260803-132318-b9f9
ext-lens-quality Aug 3, 2026 freshest ext-RMD-20260803-132318-b9f9
ext-lens-sentiment Aug 3, 2026 freshest ext-RMD-20260803-132318-b9f9
ext-lens-value Aug 3, 2026 freshest ext-RMD-20260803-132318-b9f9
scenario-valuation Aug 3, 2026 freshest RMD-20260803-124727-a9dc
valuation-synthesis Aug 3, 2026 freshest RMD-20260803-124727-a9dc

Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.

Saved History

1 frozen snapshot — the record we score once predictions mature.
MadeModelCallAt callTargetExp.Eval due
Aug 4, 2026 v0.6.0 Neutral $215.19 $221.00 +2.7% Feb 2027 viewing

Not Yet Modeled

What this v0.6.0 forecast deliberately ignores — the work ahead, in plain sight.
  • Scenario probabilities — one path, no bull/bear split (base_prob = 1.0).
  • Intraday / sub-2-week behaviour — the first claim is at 14 days by design (EOD product).
  • Position sizing / portfolio context — the path is a price claim only.